COVID-19 Human IgG PharmaGenie ELISA Kit (N-Protein) (SBRS1719)

An indirect immunoassay from Assay Genie quantifies human IgG antibodies directed against the SARS-CoV-2 nucleocapsid (N) protein, supporting seroprevalence studies, vaccine-response profiling, and post-infection immunity screening in research settings.

Unlike spike-protein-targeted assays, the platform measures antibodies against the internal N-protein, a target linked to longer-lasting humoral responses and useful for distinguishing natural infection from vaccination within research cohorts. Each 96-assay kit is supplied in a microplate configuration with an absorbance-based read-out on a standard laboratory plate reader.

The in vitro assay accommodates dried blood spot, plasma, saliva, and serum specimens, broadening feasibility for decentralized and at-home sample collection workflows. Reagents are supplied refrigerated and remain stable through the stated shelf life when stored appropriately. Researchers preparing aliquots from freshly collected samples preserve immunoglobulin integrity for downstream testing.